HDAC9 and leukemia: Monotherapy with CUDC-907 not only outperformed single-target inhibitors of HDAC and PI3K but also significantly extended the survival of leukemia-bearing mice compared to the traditional chemotherapy combination of vincristine and dexamethasone (Fig. 6a).